Hormonal therapies in acne

Bibliography

• HAMILTON JB: Male hormone substance: a prime factor in acne. Clin. Endocrinol Metab. (1941) 1:570–592.
   Google Scholar
• •The classic first paper to show the importance of male hormones in acne
   Google Scholar
• POCHI PE, STRAUSS JS, MESCON H: Sebum secretion and urinary fractional 17-ketosteroid and total 17-hydoxycorticoid excretion in male castrates. J. Invest. Dermatol (1962) 39:475–483.
   PubMedGoogle Scholar
• •An important addition to [1], this study proves that replacement of testosterone in castrates restores sebum production and acne.
   Google Scholar
• LOOKINGBILL DP, HORTON R, DEMERS LM, EGAN N, MARKS JG JR, SANTEN RJ: Tissue production of androgens in women with acne. Am. Acad. Dermatol (1985) 12:481–487.
   PubMed Web of Science ®Google Scholar
• THIBOUTOT D, GILLILAND K, LIGHT J, LOOKINGBILL D: Androgen metabolism in sebaceous glands from subjects with and without acne. Arch. Dermatol (1999) 135:1041–1045.
   PubMed Web of Science ®Google Scholar
• •In this study, serum levels of DHEAS, androstenedione, testosterone, and DHT were significantly higher in women with acne than those without acne.
   Google Scholar
• LUCKY AW, BIRO FM, SIMBARTL LA, MORRISON JA, SORG NW: Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinial study. J. Pediatr. (1997) 130:30–39.
   PubMedGoogle Scholar
• VEXIAU P, HUSON C, CHIVOT M et al.: Androgen excess in women with acne alone compared with women with acne and/or hirsutism. J. Invest. Dermatol (1990) 94:279–283.
   PubMed Web of Science ®Google Scholar
• SLAYDEN SM, MORAN C, SAMS WM JR, BOOTS LR, AZZIZ R: Hyperandro-genemia in patients presenting with acne. Feral. Stern. (2001) 75:889–892.
   PubMed Web of Science ®Google Scholar
• CIBULA D, HILL M, VOHRADNIKOVA O, KUZEL D, JANTA M, ZIVNY J: The role of androgens in determining acne severity in adult women. Br. Dermatol (2000) 143:399–404.
   PubMed Web of Science ®Google Scholar
• •In 90 women with acne, elevated levels of at least one androgen were found in 73 subjects (81%), but no correlation could be made between the grade of acne severity and laboratory markers of androgenicity.
   Google Scholar
• DEPLEWSKI D, ROSENFIELD RL: Role of hormones in pilosebaceous unit development. Endocr. Rev (2000) 21:363–392.
   PubMed Web of Science ®Google Scholar
• ••This is a superb review of pilosebaceousphysiology, from embryology to therapy.
   Google Scholar
• FRITCSH M, ORFANOS CE, ZOUBOULIS CC: Sebocytes are the key regulators of androgen homeostasis in human skin. J. Invest. Dermatol (2001) 116:793–800.
   PubMedGoogle Scholar
• ••This review clarifies the importance ofandrogen metabolism and homeostasis at the sebaceous gland level.
   Google Scholar
• IMPERATO-MCGINLEY J, GAUTIER T, CAI L et al.: The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. I. Clin. Endocrinol Metab. (1993) 76:524–528.
   PubMed Web of Science ®Google Scholar
• ••First paper to show that sebum productionis normal in individuals with 5a-reductase deficiency (pseudohermaphroditism), and absent in individuals with androgen receptor disorders (androgen insensitivity syndromes).
   Google Scholar
• THIBOUTOT D, BAYNE E, THORNE J et al.: Immunolocalization of 5-alpha-reductase isozymes in acne lesions and normal skin. Arch. Dermatol (2000) 136:1125–1129.
   PubMedGoogle Scholar
• THIBOUTOT D, HARRIS G, ILES V, CIMIS G, GILLILAND K, HAGARI S: Activity of the Type 15 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J. Invest. Dermatol (1995) 105:209–214.
   PubMed Web of Science ®Google Scholar
• •First paper to show that acne prone skin has enriched levels of 5 a-reductase Type 1.
   Google Scholar
• TOTH I, SZECSI M, JULESZ J, FAREDIN I: Activity and inhibition of 3-3-hydroxysteroid dehydrogenase/A-5-4-isomerase in human skin. Skin Pharmacol (1997) 10:160–168.
   PubMedGoogle Scholar
• CHOUDHRY R, HODGINS MB, VANDR KWAST TH, BRINKMANN AO, BOERSMA WJ: Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J. Endocrinol (1992) 133:467–475.
   PubMed Web of Science ®Google Scholar
• •Androgen receptors are identified in skin through immunohistochemistry techniques.
   Google Scholar
• LIANG T, HOYER S, YU R, SOLTANI K, LORINCZ AL, HIIPAKKA RA, LIAO S: Immunocytochemical localization of androgen receptors in human skin using monoclonal antibodies against the androgen receptor. Invest. Dermatol (1993) 100:663–666.
   PubMed Web of Science ®Google Scholar
• •Using a highly specific antibody made against the N-terrninus of the androgen receptor, androgen receptor localisation is demonstrated in skin.
   Google Scholar
• SAWAYA ME, SHALITA AR: Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. .1. Caton. Med. Surg. (1998) 3:9–15.
   PubMedGoogle Scholar
• ZOUBOULIS CC, XIA L, AKAMATSU H et al.: The human sebocyte culture model provides new insights into development and management of seborrhea and acne. Dermatology (1998) 196:21-31. •In vitro stimulation of sebocyte proliferation by androgens could be completely abolished by spironolactone. The investigators also stimulated sebocyte proliferation with insulin, thyroid-stimulating hormone and hydrocortisone, suggesting that the hormonal control of the sebaceous gland is complex.
   Google Scholar
• RABE T, KOWALD A, ORTMANN J, REHBERGER-SCHNEIDER S: Inhibition of skin 5a-reductase by oral contraceptive progestins in vitro. Cynecol Endocrinol (2000) 14:223–230.
   PubMed Web of Science ®Google Scholar
• MANT J, PAINTER R, VESSEY M: Risk of myocardial infarction, angina and stroke in users of oral contraceptives: an updated analysis of a cohort study. Br. J. Obstet. Cynaecol. (1998) 105:890–896.
   PubMedGoogle Scholar
• •Prospective cohort study of 17,032 women showed a slight increase in risk of ischaemic stroke in current users and an increase in risk for myocardial infarction in heavy smokers.
   Google Scholar
• LEMAY A, DEWAILLY SD, GRENIER R, HUARD J: Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and D,L-norgestrel. I Clin. Endocrinol Metab. (1990) 71:8–14.
   PubMed Web of Science ®Google Scholar
• CHAROENVISAL C, THAIPISUTTIKUL Y, PINJAROEN S, KRISANAPAN O, BENJAWANG W: Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. hat. J. Fertil. (1996) 41:423–429.
   Google Scholar
• DIEBEN TO, VROMANS L, THEEUWES A, BENNINK HJ: The effects of CTR-24, a biphasic oral contraceptive combination, compared to Diane-35 in women with acne. Contraception (1994) 50:373–382.
   PubMed Web of Science ®Google Scholar
• THIBOUTOT D, ARCHER DF, LEMAY A, WASHENIK K, ROBERTS J, HARRISON DD: A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. Feral Steil]. (2001) 76:461–468.
   PubMed Web of Science ®Google Scholar
• •A well-designed study of Alesse in acne showing significant improvement when compared with placebo.
   Google Scholar
• CONEY P, WASHENIK K, LANGLEY RG, DIGIOVANNA JJ, HARRISON DD: Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception (2001) 63:297–302.
   PubMed Web of Science ®Google Scholar
• •Alesse is well tolerated.
   Google Scholar
• ROSENBERG MJ, MEYERS A, ROY V: Efficacy, cycle control and side effects of low-and lower-dose oral contraceptives: a randomized trial of 20 lig and 35 lig estrogen preparations. Contraception (2000) 60:321-329. •Mircette users reported 43% acne decrease. Alesse users reported 19% acne decrease.
   Google Scholar
• THORNEYCROFT IH, STANCZYK FZ, BRADSHAW KD, BALLAGH SA, NICHOLS M, WEBER ME: Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception (1999) 60:255-262. •Two low-dose oral contraceptives containing 0.02 mg EE were well tolerated and effective in acne.
   Google Scholar
• LUCKY AW, HENDERSON TA, OLSON WH, ROBISCH DM, LEBWOHL M, SWINYER LJ: Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J. Am. Acad. Dermatol. (1997) 37:746–754.
   PubMed Web of Science ®Google Scholar
• •Approximately 50% improvement of acne was confirmed in this well-designed trial.
   Google Scholar
• REDMOND GP, OLSON WH, LIPPMAN JS, KAFRISSEN ME, JONES TM, JORIZZO JL: Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet. Gynecol (1997) 89:615–622.
   PubMed Web of Science ®Google Scholar
• •This trial is similar to the one above, carefully designed, showing acne improvement with Ortho Tri-Cyclen compared to placebo.
   Google Scholar
• KAPLAN B: Desogestrel, norgestimate, and gestodene: the newer progestins. Ann. Pharmacother: (1995) 29:736–742.
   PubMed Web of Science ®Google Scholar
• •A valuable review of the newer generation of progestins..
   Google Scholar
• VASILAKIS-SCARAMOZZA C, JICK H: Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet (2001) 358:1427–1429.
   PubMed Web of Science ®Google Scholar
• ROMIEU I, BERLIN JA, COLDITZ G:Oral contraceptives and breast cancer. Review and meta-analysis. Cancer (1990) 66:2253–2263.
   Google Scholar
• RUSHTON L, JONES DR: Oral contraceptive use and breast cancer risk: a meta-analysis of variations with age at diagnosis, parity and total duration of oral contraceptive use. Br. J. Obstet. Gynaecol (1992) 99:239–246.
   PubMedGoogle Scholar
• HAWLEY W, NUOVO J, DENEEF CP, CARTER P: Do oral contraceptive agents affect the risk of breast cancer? A meta-analysis of the case-control reports. J. Am. Board Fam. Pract. (1993) 6:123–135.
   PubMedGoogle Scholar
• COLLABORATIVE GROUP ON HORMONAL FACTORS IN BREAST CANCER: Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet (1996) 347: 1713-1727.
   Google Scholar
• SCHLESSELMAN JJ: Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstet. Gynecol (1995) 85:793–801.
   PubMed Web of Science ®Google Scholar
• KRATTENMACHER R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception (2000) 62:29–38.
   PubMed Web of Science ®Google Scholar
• •A review of drospirenone, a new progestin that may have better tolerability in some individuals.
   Google Scholar
• FREEMAN EW, KROLL R, RAPKIN A, PEARLSTEIN T, BROWN C, PARSEY K et al.: Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. Womens Health Gend. Based Med. (2001) 10:561–569.
   PubMedGoogle Scholar
• MANSOUR D: Yasmin - a new oral contraceptive, a new progestogen: the reasons why. Eur. Contracept. Reprod. Health Care (2000) 5\(Suppl. 3):9–16.
   Google Scholar
• FOIDART JM: The contraceptive profile of a new oral contraceptive with antimineralo-corticoid and antiandrogenic effects. Eur. Contracept. Reprod. Health Care (2000) 5\(Suppl. 3):25–33.
   Google Scholar
• CONN PM, CROWLEY WF JR: Gonado-tropin-releasing hormone and its analogues. N Engl. J. Med. (1991) 324:93–103.
   PubMed Web of Science ®Google Scholar
• •A thorough review of the uses of GnRH analogues.
   Google Scholar
• RITTMASTER RS: Gonadotropin-releasing hormone (GnRH) agonists and estrogen/progesterone replacement for the treatment of hirsutism: evaluating the results. Clin. Endocrinol Metab. (1995) 80:3403–3405.
   Google Scholar
• PAZOS F, ESCOBAR-MORREALE HF, BALSA J, SANCHO JM, VARELA C: Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism. Feral Steil]. (1999) 71:122–128.
   PubMed Web of Science ®Google Scholar
• •GnRH agonist triptorelin was not as effective as flutarnide or cyproterone acetate in the treatment of hirsutism in 33 patients.
   Google Scholar
• CARIVIINA E: A risk-benefit assessment of pharmacological therapies for hirsutism. Drug Sal: (2001) 24:267-276. •In this review, GnRH agonists are assessed as being a second-line approach; androgen receptor blockers are the most effective therapies in hirsutism.
   Google Scholar
• LOUGHLIN T, CUNNINGHAM S, MOORE A, CULLITON M, SMYTH PPA, MCKENNA TJ: Adrenal abnorm-alities in polycystic ovary syndrome. J. Clin. Endocrinol Metab. (1986) 62:142–147.
   PubMed Web of Science ®Google Scholar
• WIEBE RH, MORRIS CV: Effect of an oral contraceptive on adrenal and ovarian androgenic steroids. Obstet. Gynecol (1984) 63:12–14.
   PubMed Web of Science ®Google Scholar
• ELDAR-GEVA T, HURWITZ A, VECSEI P, PALTI Z, MILWIDSKY A, ROSLER A: Secondary biosynthetic defects in women with late-onset congenital adrenal hyperplasia. N Engl. J. Med. (1990) 323:855–863.
   PubMedGoogle Scholar
• SPEISER PW, DUPONT B, RUBINSTEIN P, PIAZZA A, KASTELAN A, NEW MI: High frequency of nonclassical steroid 21-hydroxylase deficiency. Am. J. Hum. Genet. (1985) 37:650–667.
   PubMed Web of Science ®Google Scholar
• •LOCAH was found to be present in 3.7% of Ashkenazi Jewish women.
   Google Scholar
• NADER S, RODRIGUEZ-RIGAU LJ, SMITH KD, STEINBERGER E: Acne and hyperandrogenism: impact of lowering androgen levels with glucocorticoid treatment. Am. Acad. Dermatol (1984) 11:256–259.
   PubMedGoogle Scholar
• •In 158 patients treated with prednisone 7.5-15 mg/day, serum testosterone levels decreased in the majority, acne cleared in 41% and significantly improved in 50%.
   Google Scholar
• PLACZEK M, DEGITZ K, SCHMIDT H, PLEWIG G: Acne fulminans in late-onset congenital adrenal hyperplasia. Lancet (1999) 354(9180):739–740.
   PubMedGoogle Scholar
• •First report of LOCAH in men with acne.
   Google Scholar
• SERAFINI PC, CATALINO J, LOBO RA: The effect of spironolactone on genital skin 5 a-reductase activity. Steroid Biochem. (1985) 23:191-194. •In vitro demonstration of inhibition of 5a-reductase by spironolactone at 1.2 x 10-5M concentration.
   Google Scholar
• OBER KP, HENNESSY JF: Spironolactone therapy for hirsutism in a hyperandrogenic woman. Ann. Intern. Med. (1978) 89:643–644.
   PubMedGoogle Scholar
• •First report of clinical antiandrogen effect of spironolactone.
   Google Scholar
• GOODFELLOW A, ALAGHBAND-ZADEH J, CARTER G et al.: Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br. Dermatol (1984) 111:124–125.
   Google Scholar
• BURKE BM, CUNLIFFE WJ: Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br. Dermatol (1985) 112:124–125.
   PubMed Web of Science ®Google Scholar
• HATWAL A, BHATT RP, AGRAWAL JK et al.: Spironolactone and cimetidine in treatment of acne. Acta Dermatol Venereol (Stockholm) (1988) 68:84–87.
   PubMedGoogle Scholar
• MUHLEMANN ME CARTER GD, CREAM JJ et al.: Oral spironolactone: an effective treatment for acne vulgaris in women. Br: J. Dermatol (1986) 115:227–232.
   Google Scholar
• SHAW JC: Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. Am. Acad. Dermatol (2000) 43:498–502.
   PubMed Web of Science ®Google Scholar
• •In women with acne who had failed antibiotics, contraceptives or isotretinoin, 66% cleared or significantly improved with spironolactone 50–100 mg/day in this open study.
   Google Scholar
• SHAW JC: Spironolactone in dermatologic therapy. Am. Acad. Dermatol (1991) 24:236–243.
   PubMedGoogle Scholar
• •Review of the history of spironolactone as antiandrogen, and its uses in acne, hirsutism and androgenetic alopecia.
   Google Scholar
• CUSAN L, DUPONT A, GOMEZ JL, TREMBLAY RR, LABRIE F: Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil. Steril (1994) 61:281–287.
   PubMed Web of Science ®Google Scholar
• •In this randomised trial with 53 women, flutamide 250 mg b.i.d. was superior to spironolactone 50 mg b.i.d. in treating hirsutism and acne.
   Google Scholar
• ERENUS M, GURBUZ O, DURMUSOGLU F et al.: Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. Feral Sterd. (1994) 61:613–616.
   PubMed Web of Science ®Google Scholar
• WONG IL, MORRIS RS, CHANG L et al.: A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. Clin. Endocrinol Metab. (1995) 80:233–238.
   Google Scholar
• ERENUS M, YUCELTEN D, GURBUZ O et al: Comparison of spironolactone-oral contraceptive vs. Cyproterone acetate-estrogen regimens in the treatment of hirsutism. Feral Sterd. (1996) 66:216–219.
   Google Scholar
• MOGHETTI P, TOSI F, TOSTI A et al.: Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial." Clin. Endocrinol Metab. (2000) 85:89–94.
   Google Scholar
• FARQUHAR C, LEE O, TOOMATH R, JEPSON R: Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne (Cochrane Review). Cochrane Database Syst. Rev (2001) 4:CD000194.
   Google Scholar
• ••In this systematic review of all randomizedclinical trials of spironolactone in hirsutism and/or acne, efficacy is established in hirsutism, but studies are currently insufficient to establish efficacy in acne.
   Google Scholar
• HOWES LG: Which drugs affect potassium. Drug Sal (1995) 12:240–244.
   PubMedGoogle Scholar
• HUGHES BR, CUNLIFFE WJ: Tolerance of spironolactone. Br. J. Dermatol (1988) 118:687–691.
   PubMed Web of Science ®Google Scholar
• •At doses of 200 mg/day, spironolactone has more menstrual and breast side effects.
   Google Scholar
• GREENBLATT DJ, KOCH-WESER J: Adverse reactions to spironolactone. PIMA (1973) 225:40–43.
   Google Scholar
• GIVRAJ KT, NOSEWORTHY TW, FRIESEN EG, SHUSTACK AS, KONOPAD EM, JOHNSTON RG: Spironolactone-induced agranulocytosis. Drug Intel]. Clin. Pharm. (1987) 21:974–975.
   PubMedGoogle Scholar
• WHITLING AM, PERGOLA PE, SANG JL, TALBERT RL: Spironolactone-induced agranulocytosis. Ann. Pharmacother: (1997) 31:582–585.
   PubMedGoogle Scholar
• FERGUSON I, FOGG C, BAUGHAN P: Spironolactone induced agranulocytosis. Med. J. Aust. (1993) 159:837.
   PubMedGoogle Scholar
• THAI KE, SINCLAIR RD: Spironolactone-induced hepatitis. Australas. Dermatol (2001) 42:180–182.
   PubMedGoogle Scholar
• WATHEN CG, MACDONALD T, WISE LA: Eosinophilia associated with spironolactone. Lancet (1986) 1:919–920.
   PubMedGoogle Scholar
• BARKER DJP: The epidemiological evidence relating to spironolactone and malignant disease in man. Drug Dev. (1987) l\(Suppl. 2):22–25.
   Google Scholar
• SHAW JC, WHITE LE: Long-term safety of spironolactone in acne: results of an 8-year follow-up study. I Caton. Med. Surg. (2002). In Press.
   Google Scholar
• CUSAN L, DUPONT A, BELANGER A et al.: Treatment of hirsutism with the pure antiandrogen flutamide. I Am. Acad. Dermatol (1990) 23:462–469.
   PubMed Web of Science ®Google Scholar
• •First report of successful use of flutamide in hirsutism.
   Google Scholar
• WANG HS, WANG TH, SOONG YK: Low dose flutamide in the treatment of acne vulgaris in women with or without oligomenorrhea or amenorrhea. Changgeng Yi Xue Za Zhi (1999) 22:423–432.
   PubMedGoogle Scholar
• •Doses of 125 mg b.i.d. are effective in hirsutism, and reduce potential side effects.
   Google Scholar
• MILLER JA, WOJNAROWSKA FT, DOWD PM, ASHTON RE, O'BRIEN TJ, GRIFFITHS WA et al.: Anti-androgen treatment in women with acne: a controlled trial. Br: J. Dermatol (1986) 114:705–716.
   Google Scholar
• HAMMERSTEIN J, MECKIES J, LEO-ROSSBERG I, MOLTZ L, ZIELSKE F: Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. .1 Steroid Biochem. (1975) 6:827–836.
   Google Scholar
• VARTIAINEN M, DE GEZELLE H, BROEKMEULEN CJ: Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate. Ear: j Contracept. Reprod. Health Care (2001) 6:46–53.
   PubMed Web of Science ®Google Scholar
• FALSETTI L, GAMBERA A, TISI G: Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. Hum. Reprod. (2001) 16:36–42
   PubMed Web of Science ®Google Scholar
• GIORDANO N, NARDI P, SANTACROCE C: Acute hepatitis induced by cyproterone acetate. Ann. Pharmacother. (2001) 35:1053–1055.
   PubMed Web of Science ®Google Scholar
• KASPER P: Cyproterone acetate: a genotoxic carcinogen? Pharmacol Toxicol (2001) 88:223–231.
   PubMedGoogle Scholar
• ERENUS M, YUCELTEN D, DURMUSOGLU F, GURBUZ O: Comparison of finasteride versus spironolactone in the treament of idiopathic hirsutism. Feral. Steril (1997) 68:1000–1003.
   PubMed Web of Science ®Google Scholar
• YUCELTEN D, ERENUS M, GURBUZ O, DURMUSOGLU F: Recurrence rate of hirsutism after 3 different antiandrogen therapies. Am. Acad. Dermatol (1999) 41:64–68.
   PubMed Web of Science ®Google Scholar
• •Hirsutism improved equally with spironolactone, cyproterone acetate and flutarnide, but returned within 1 year after treatment was stopped.
   Google Scholar
• TREMBLAY MR, LUU-THE V, LEBLANC G et al.: Spironolactone-related inhibitors of Type Ill7P-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/ antiproliferative activities. Bioorg. Med. Chem. (1999) 7: 10 13–1023.
   Google Scholar
• MALTAIS R, LUU-THE V, POIRIER D: Parallel solid-phase synthesis of 33-peptido-3a-hydroxy-5a-androstan-17-one derivatives for inhibition of Type 3 17P- hydroxysteroid dehydrogenase. Bi000rg. Med. Chem. (2001) 9:3101–3111.
   Google Scholar
• CUNLIFFE WJ, BOTTOMLEY WW: Antiandrogens and acne. A topical approach? Arch. Dermatol (1992) 128:1261–1264.
   PubMedGoogle Scholar
• •A succinct review of topical antiandrogens.
   Google Scholar
• SINTOV A, SERAFIMOVICH S, GILHAR A: New topical antiandrogenic formulations can stimulate hair growth in human bald scalp grafted onto mice. Int. Pharm. (2000) 194:125–134.
   PubMed Web of Science ®Google Scholar
• MATIAS JR, GAILLARD M: Local inhibition of sebaceous gland growth by topically applied RU58841. Ann. NY Acad. Sci. (1995) 761:56–65.
   PubMedGoogle Scholar
• •A 60% reduction in sebaceous gland size was observed in this study of Syrian hamster ear sebaceous gland model, with no systemic effect.
   Google Scholar
• CHEN C, LI X, SINGH SM, LABRIE F: Activity of 1713-(N-alkyl/arylformamido) and 17P-[(N-alkyl/aryl) alkyl/arylamido]-4-methyl-aza-5a-androstan-3-ones as 5a-reductase inhibitors in the hamster flank organ and ear. J. Invest. Dermatol (1998) 111:273–278.
   PubMedGoogle Scholar
• YE F, IMAMURA K, IMANISHI N, RHODES L, UNO H: Effects of topical antiandrogen and 5-a-reductase inhibitors on sebaceous glands in male fuzzy rats. SIMI Pharmacol (1997) 10:288–297.
   Google Scholar
• LOOKINGBILL DP, ABRAMS BB, ELLISCN et al.: Inocoterone and acne. The effect of a topical antiandrogen: results of a multicenter clinical trial. Arch. Dermatol (1992) 128:1197–1200.
   PubMedGoogle Scholar
• •Topical inocoterone produced 26% reduction of inflammatory acne lesions compared to 13% reduction with placebo.
   Google Scholar
• YAMAMOTO A, ITO M: Topical spironolactone reduces sebum secretion rates in young adults. J. Dermatol. (1996) 23:243–246.
   PubMedGoogle Scholar
• GRUBER DM, SATOR MO, JOURA EA et al.: Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial. Arch. Dermatol (1998) 134:459–463.
   PubMed Web of Science ®Google Scholar
• STEWART FH, HARPER CC, ELLERTSON CE, GRIMES DA, SAWAYA GF, TRUSSELL J: Clinical breast and pelvic examination requirements for hormonal contraception: Current practice versus evidence. JAMA (2001) 285(17):2232–2239.
   PubMed Web of Science ®Google Scholar
• ••This review is an invaluable resource forphysicians wishing to use oral contraceptives in their patients. Indications, risks, precautions and contraindications are presented.
   Google Scholar